Hormone replacement therapy enhances postprandial lipid metabolism in postmenopausal women

Metabolism: Clinical and Experimental

Volumn 48, Issue 9, 1999, Pages 1193-1196

  Weintraub, Moshe ^a   Grosskopf, Itamar ^a,b   Charach, Gideon ^a   Eckstein, Nachman ^a   Rubinstein, Ardon ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CHYLOMICRON; CONJUGATED ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; RETINOL PALMITATE; TRIACYLGLYCEROL;

ARTICLE; BODY FAT; CHOLESTEROL BLOOD LEVEL; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; LIPID BLOOD LEVEL; LIPID METABOLISM; POSTMENOPAUSE; POSTPRANDIAL STATE; PRIORITY JOURNAL;

EID: 0032844477     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(99)90137-3     Document Type: Article

References (32)

1. Udoff L, Langenberg P, Adashi EY: Combined continuous hormone replacement therapy: A critical review. Obstet Gynecol 86:306-316, 1995
2. Hulley S, Grady D, Bush T. et al: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 280:605-613, 1998
3. PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Intervention. JAMA 273:199-208, 1995
4. Westerveld HT, Kock LAW, van Rijn HJM, et al: β-estradiol improves postprandial lipid metabolism in postmenopausal women. J Clin Endocrinol Metab 80:249-253, 1995
5. Zilversmit DB: Atherogenesis: Apostprandialphenomenon. Circulation 60:473-485, 1979
6. Floren CH, Albers JJ, Bierman EL: Uptake of chylomicron remnants causes cholesterol accumulation in cultured human arterial smooth muscle cells. Biochim Biophys Acta 663:336-349, 1981
7. Stender S, Zilversmit DB: Arterial influx of esterified cholesterol from two plasma lipoprotein fractions and its hydrolysis in vivo in hypercholesterolemics. Atherosclerosis 39:97-109, 1981
8. Stender S, Zilversmit DB: Comparison of cholesterol ester transfer from chylomicrons and other plasma lipoproteins to aorta intima media of cholesterol-fed rabbit. Arteriosclerosis 2:493-499, 1982
9. Gianturco SH, Lin AH, Hwang SL, et al: Distinct murine macrophage receptor pathway for human triglyceride-rich lipoproteins. J Clin Invest 82:1633-1643, 1988
10. Nordestgraad BE, Nielsen LB: Atherosclerosis and arterial influx of lipoproteins. Curr Opin Lipidol 5:252-257, 1994
11. Ginsberg HN: Lipoprotein metabolism and its relation to atherosclerosis. Med Clin North Am 78:1-17, 1994
12. Redgrave TG: Postprandial remnants and their relation to atherosclerosis, in DeGennes JL, Polonovski J, Paoletti R (eds): Latent Dyslipoproteinemias and Atherosclerosis. New York, NY, Reaven, 1984, pp 9-15
13. Weintraub MS, Eisenberg S, Breslow JL: Different patterns of postprandial metabolism in normals and type IIa, type III and type IV hyperlipoproteinemics: Effect of treatment with cholestyramine and gemfibrozil. J Clin Invest 79:1110-1119, 1987
14. Cortner JA, Coates PM, Le NA, et al: Kinetics of chylomicron remnant clearance in normal and hyperlipoproteinemic subjects. J Lipid Res 28:195-206, 1987
15. Blomhoff R, Rasmussen M, Nelsen A. et al: Hepatic retinal metabolism. J Biol Chem 260:13560-13565, 1985
16. DeRuyter MG, De-Leenheer AP: Simultaneous determination of retinol and retinyl esters in serum or plasma by reversed-phase high performance liquid chromatography. Clin Chem 24:1920-1923, 1978
17. Berr F, Eckel RH, Kern F: Plasma decay of chylomicron remnants is not affected by heparin-stimulated plasma lipolytic activity in normal fasting man. J Lipid Res 26:852-859, 1985
18. Wenham P, Price WH: Apolipoprotein E genotyping by one stage PCR. Lancet 337:1158-1159, 1991
19. Kable WT, Gallagher JC, Nachtigall L, et al: Lipid changes after hormone replacement therapy for menopause. J Reprod Med 35:512-518, 1990
20. Lobo RA, Pickar JH, Wild RA, et al: Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 84:987-995, 1994
21. Feldman EB, Wang CI. Adelsberg D: Effect of prolonged use of estrogen on circulating lipids in patients with idiopathic hyperlipidemia. Circulation 20:234-242, 1959
22. Chait A, Brunzell JD, Albers JJ, et al: Type III hyperlipoprotein-emia ("remnant removal disease"): Insight into the pathogenic metabolism. Lancet 1:1176-1178, 1977
23. Archer DF, Pickar JH, Bottiglioni F: Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 83:686-692, 1994
24. Follmann D. Elliott P, Suh I, et al: Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 45:769-773, 1992
25. Bewtra C, Kable WT, Gallagher JC: Endometrial histology and bleeding patterns in menopausal women treated with estrogen and continuous or cyclic progestin. J Reprod Med 33:205-208, 1988
26. Christiansen C, Riis BJ: 17Beta-estradiol and continuous norethisterone: A unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 7:836-841, 1990
27. Weintraub MS, Zechner R, Brown A, et al: Dietary polyunsaturated fats of ω-6 and ω-3 series reduce postprandial lipoprotein levels. Chronic and acute effects of fat saturation on postprandial lipoprotein metabolism. J Clin Invest 82:1884-1893, 1988
28. Weintraub MS, Rosen Y, Otto R, et al: Physical exercise conditioning in the absence of weight loss reduces fasting and postprandial triglyceride-rich lipoprotein levels. Circulation 79:1007-1014, 1989
29. Brunzell JD, Hazzard WR, Porte D Jr, et al: Evidence for the common saturable triglyceride removal mechanism for chylomicrons and very low density lipoprotein in man. J Clin Invest 52:1578-1585, 1973
30. Walsh BW, Sacks FM: Effects of low dose oral contraceptives on very low density lipoprotein metabolism. J Clin Invest 91:2126-2132, 1973
31. Campos H, Walsh BW, Judge H, et al: Effect of estrogen on very low density lipoprotein and low density lipoprotein subclasses metabolism in postmenopausal women. J Clin Endocrinol Metab 82:3955-3963, 1997
32. Muesing RA, Miller VT, LaRosa JC. et al: Effects of unopposed conjugated equine estrogen on lipoprotein composition and apolipoprotein-E distribution. J Clin Endocrinol Metab 75:1250-1254, 1992